TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20308972

Group type: EXPERIMENTAL
Intervention: 2 g of arginine ingested in a single dose 60 minutes prior to exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Arginine and placebo trials
Number of subjects: 6
Study: 17640944

Group type: EXPERIMENTAL
Intervention: HP-hMG
Number of subjects: 731

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 731
Study: 16291760

Group type: EXPERIMENTAL
Intervention: Synthetic protein N (10, 30, or 100 microg/dose)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Synthetic protein R (10, 30, or 100 microg/dose)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Synthetic protein C (10, 30, or 100 microg/dose)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 12165692

Group type: EXPERIMENTAL
Intervention: Endurance+Strength (ES) training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Endurance-only (E) training
Number of subjects: 15
Study: 9479340

Group type: EXPERIMENTAL
Intervention: CytoRich liquid-based preparation (AutoCyte, Inc.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional smear
Number of subjects: 0
Study: 8558939

Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg/m2 orally)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Allopurinol (one dose)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Allopurinol (concomitant with methotrexate therapy)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Methotrexate therapy only
Number of subjects: 46
Study: 1888308

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 80
Study: 6184574

Group type: EXPERIMENTAL
Intervention: 20 mg nitrendipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg nitrendipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31599256

Group type: EXPERIMENTAL
Intervention: F-75 and F-100 recipes
Number of subjects: 92

Group type: COMPARATOR
Intervention: Prepackaged F-75 & F-100 formulae
Number of subjects: 92
Study: 28877748

Group type: EXPERIMENTAL
Intervention: GSK2586881 (0.4 mg/kg) administered twice daily for 3 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 26071863

Group type: EXPERIMENTAL
Intervention: Web-Based Tracking Group (Fitbit intervention)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pedometer Group (Control)
Number of subjects: 51
Study: 23602601

Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo, trastuzumab, and docetaxel
Number of subjects: 808
Study: 21825268

Group type: EXPERIMENTAL
Intervention: COM‐ON‐p (concise and individualized communication skills training)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 41
Study: 19255706

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nasogastric tube nutrition (NGTN)
Number of subjects: 81
Study: 17129383

Group type: EXPERIMENTAL
Intervention: Paclitaxel at a dose of 175, 210, or 250 mg/m2
Number of subjects: 474
Study: 15577337

Group type: EXPERIMENTAL
Intervention: Radial forearm flap
Number of subjects: 41

Group type: COMPARATOR
Intervention: Thinned anterolateral thigh cutaneous flap
Number of subjects: 41
Study: 11401123

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 1485787

Group type: EXPERIMENTAL
Intervention: Biofragmentable intraluminal ring (Valtrac)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Suture of the cholecystointestinal anastomosis
Number of subjects: 20
Study: 6695162

Group type: EXPERIMENTAL
Intervention: Long acting beta blocker (oxprenolol R 160 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Basic conditions
Number of subjects: 12
Study: 30807294

Group type: EXPERIMENTAL
Intervention: Modified dual therapy
Number of subjects: 232

Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy
Number of subjects: 232
Study: 30333004

Group type: EXPERIMENTAL
Intervention: Multicomponent positive psychology intervention ('Living well with bipolar disorder') in addition to usual care (CAU)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care (CAU)
Number of subjects: 112
Study: 27351244

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 194
Study: 24615215

Group type: EXPERIMENTAL
Intervention: Chinese traditional healthcare exercises (CTHE)
Number of subjects: 136

Group type: COMPARATOR
Intervention: the 8th radio calisthenics (control)
Number of subjects: 136
Study: 22773713

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Open-label Azithromycin
Number of subjects: 97
Study: 20190028

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2 x 600 mg/daily for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18681082

Group type: EXPERIMENTAL
Intervention: Home rodent-specific environmental intervention
Number of subjects: 150
Study: 15823451

Group type: EXPERIMENTAL
Intervention: Shortened version of the ACQ (symptoms alone)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Shortened version of the ACQ (symptoms plus FEV1)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Shortened version of the ACQ (symptoms plus short‐acting beta2‐agonist)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Original ACQ
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: All four versions of the ACQ
Number of subjects: 552
Study: 12753323

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal using Simulect (IL-2 receptor inhibitor)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard maintenance immunosuppression including prednisone
Number of subjects: 23
Study: 10839763

Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg orally once a week for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8604669

Group type: EXPERIMENTAL
Intervention: Fat-modified dairy products
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional dairy products
Number of subjects: 33
Study: 1859658

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2860043

Group type: EXPERIMENTAL
Intervention: Steroids or a combination with prednisolone and sulfasalazine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo or sulfasalazine alone
Number of subjects: 130
Study: 31918692

Group type: EXPERIMENTAL
Intervention: Written materials
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Video materials
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no materials)
Number of subjects: 98
Study: 29898870

Group type: EXPERIMENTAL
Intervention: Vaccine regimen (intramuscular injection of ALVAC-HIV vector [vCP2438] at 0, 1, 3, 6, and 12 months plus bivalent subtype C gp120 and MF59 adjuvant at 3, 6, and 12 months)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Vaccine regimen
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 26561619

Group type: EXPERIMENTAL
Intervention: 5‐MTHF
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136

Group type: COMPARATOR
Intervention: FO+5‐MTHF
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: FO
Number of subjects: 136
Study: 25193718

Group type: EXPERIMENTAL
Intervention: Alcohol electronic screening and brief intervention (AUDIT-C)
Number of subjects: 3206
Study: 23660331

Group type: EXPERIMENTAL
Intervention: Six-monthly monitoring
Number of subjects: 163
Study: 21476204

Group type: EXPERIMENTAL
Intervention: Bletilla striata particles
Number of subjects: 59

Group type: COMPARATOR
Intervention: Gelfoam particles
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study: 17698218

Group type: EXPERIMENTAL
Intervention: tirofiban infusion and sirolimus-eluting stents (SES)
Number of subjects: 175

Group type: COMPARATOR
Intervention: abciximab and bare metal stent (BMS)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: tirofiban infusion and SES
Number of subjects: 175

Group type: COMPARATOR
Intervention: abciximab and BMS
Number of subjects: 175
Study: 16538150

Group type: EXPERIMENTAL
Intervention: CT scoring system for CF lung disease
Number of subjects: 16
Study: 14510794

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 14
Study: 11015240

Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nebulized salbutamol
Number of subjects: 120
Study: 8630674

Group type: EXPERIMENTAL
Intervention: Comprehensive risk factor modification program (nonpharmacological intervention)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 164
Study: 1451242

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 M units) administered over 30 minutes
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 6487497

Group type: EXPERIMENTAL
Intervention: Metoprolol (100-200 mg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31661077

Group type: EXPERIMENTAL
Intervention: Glucose feedback (4 weeks) followed by glucose and physical activity feedback (2 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Physical activity feedback (4 weeks) followed by biobehavioral feedback (2 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Biobehavioral feedback (6 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fitbit usage
Number of subjects: 45
Study: 29150421

Group type: EXPERIMENTAL
Intervention: Rd continuous
Number of subjects: 1623

Group type: COMPARATOR
Intervention: Rd18
Number of subjects: 1623

Group type: COMPARATOR
Intervention: MPT
Number of subjects: 1623
Study: 25874687

Group type: EXPERIMENTAL
Intervention: TissuGlu® flap fixation
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control (mastectomy only)
Number of subjects: 205
Study: 24666195

Group type: EXPERIMENTAL
Intervention: Friendly touch on the back during a delay-of-gratification task
Number of subjects: 40

Group type: COMPARATOR
Intervention: No touch
Number of subjects: 40
Study: 22527648

Group type: EXPERIMENTAL
Intervention: Repeated interventional treatment (average 10 times, approximately 107 single injections during each treatment cycle)
Number of subjects: 38
Study: 20855664

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Baseline GDF-15 levels (per 100 ng/L)
Number of subjects: 1734
Study: 18030865

Group type: EXPERIMENTAL
Intervention: Visual medication schedule with brief counseling
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 147
Study: 15743327

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 22
Study: 11898017

Group type: EXPERIMENTAL
Intervention: Multitest regimen of 5 sacroiliac pain provocation tests
Number of subjects: 78
Study: 10594409

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 7588454

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) monotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2167330

Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin-stimulated interleukin-2 production on day 5 after rhinovirus inoculation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin-stimulated interferon-gamma production on day 5 after rhinovirus inoculation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural killer cell-mediated cytotoxicity on day 5 after rhinovirus challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific antigen-stimulated blastogenesis on day 21 after rhinovirus challenge
Number of subjects: 0
Study: 6985776

Group type: EXPERIMENTAL
Intervention: Cimetidine prophylaxis
Number of subjects: 0
Study: 31654469

Group type: EXPERIMENTAL
Intervention: Educational leaflet on safe sleeping practices
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 189
Study: 30159720

Group type: EXPERIMENTAL
Intervention: Partially absorbable mesh
Number of subjects: 163

Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 163
Study: 28838862

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg per day)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 25452452

Group type: EXPERIMENTAL
Intervention: Nivolumab 0.3 mg/kg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nivolumab 2 mg/kg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nivolumab 10 mg/kg
Number of subjects: 168
Study: 24095246

Group type: EXPERIMENTAL
Intervention: tolcapone
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 22303711

Group type: COMPARATOR
Intervention: Chronic HBV carriers (GPS and GDS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chronic HBV patients (GPS and GDS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GPS group
Number of subjects: 40

Group type: COMPARATOR
Intervention: HBV patients group
Number of subjects: 40
Study: 19119079

Group type: EXPERIMENTAL
Intervention: Point of need access to specialist care via the nurse specialist
Number of subjects: 237

Group type: COMPARATOR
Intervention: Routine hospital based 6‐monthly clinical review
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Point of need access
Number of subjects: 237
Study: 17330628

Group type: EXPERIMENTAL
Intervention: Xpand chest drain
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard underwater drain
Number of subjects: 67
Study: 14587108

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis during laparoscopic cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (control group)
Number of subjects: 0
Study: 10877008

Group type: EXPERIMENTAL
Intervention: Effervescent paracetamol tablets (2 x 500 mg Pinex Brusetablett, Alpharma AS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ordinary paracetamol tablets (2 x 500 mg Panodil tablets, SmithKline Beecham)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Effervescent paracetamol tablets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ordinary paracetamol tablets
Number of subjects: 20
Study: 9408153

Group type: EXPERIMENTAL
Intervention: Doxorubicin-containing chemotherapy with involved field radiotherapy (n = 58)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Doxorubicin-containing chemotherapy without involved field radiotherapy (n = 18)
Number of subjects: 76
Study: 8458821

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin mixture (daily doses of 592 mg of alpha‐tocopherol equivalents, 1,000 mg of ascorbic acid, and 30 mg of beta‐carotene)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20